298 related articles for article (PubMed ID: 26414608)
1. Using multiparametric MRI to 'personalize' biopsy for men.
Mendhiratta N; Meng X; Taneja SS
Curr Opin Urol; 2015 Nov; 25(6):498-503. PubMed ID: 26414608
[TBL] [Abstract][Full Text] [Related]
2. The role of MRI in active surveillance for men with localized prostate cancer.
Recabal P; Ehdaie B
Curr Opin Urol; 2015 Nov; 25(6):504-9. PubMed ID: 26372037
[TBL] [Abstract][Full Text] [Related]
3. Stratification of the aggressiveness of prostate cancer using pre-biopsy multiparametric MRI (mpMRI).
Dwivedi DK; Kumar R; Bora GS; Thulkar S; Sharma S; Gupta SD; Jagannathan NR
NMR Biomed; 2016 Mar; 29(3):232-8. PubMed ID: 26730884
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.
Pokorny MR; de Rooij M; Duncan E; Schröder FH; Parkinson R; Barentsz JO; Thompson LC
Eur Urol; 2014 Jul; 66(1):22-9. PubMed ID: 24666839
[TBL] [Abstract][Full Text] [Related]
5. Can 3-Tesla pelvic phased-array multiparametric MRI avoid unnecessary repeat prostate biopsy in patients with PSA < 10 ng/mL?
Pepe P; Garufi A; Priolo G; Pennisi M
Clin Genitourin Cancer; 2015 Feb; 13(1):e27-30. PubMed ID: 25081324
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer.
Chu CE; Lonergan PE; Washington SL; Cowan JE; Shinohara K; Westphalen AC; Carroll PR; Cooperberg MR
Eur Urol; 2020 Oct; 78(4):515-517. PubMed ID: 32631744
[TBL] [Abstract][Full Text] [Related]
7. In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?
Salami SS; Ben-Levi E; Yaskiv O; Ryniker L; Turkbey B; Kavoussi LR; Villani R; Rastinehad AR
BJU Int; 2015 Apr; 115(4):562-70. PubMed ID: 25252133
[TBL] [Abstract][Full Text] [Related]
8. How accurately can MRI detect indolent disease?
Ouzzane A; Puech P; Villers A
Curr Opin Urol; 2014 May; 24(3):264-9. PubMed ID: 24625426
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer.
An JY; Sidana A; Choyke PL; Wood BJ; Pinto PA; Türkbey İB
Balkan Med J; 2017 Sep; 34(5):388-396. PubMed ID: 28990929
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists.
Yoo S; Kim JK; Jeong IG
Korean J Urol; 2015 Jul; 56(7):487-97. PubMed ID: 26175867
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of 3 Tesla pelvic phased-array multiparametric MRI in diagnosing prostate cancer at repeat biopsy.
Pepe P; Garufi A; Priolo G; Dibenedetto G; Salemi M; Pennisi M; Fraggetta F; Aragona F; Barbera M
Arch Ital Urol Androl; 2014 Dec; 86(4):336-9. PubMed ID: 25641466
[TBL] [Abstract][Full Text] [Related]
12. MRI to guide biopsies or avoid biopsies?
Winoker JS; Pinto PA; Rastinehad AR
Curr Opin Urol; 2018 Nov; 28(6):522-528. PubMed ID: 30239414
[TBL] [Abstract][Full Text] [Related]
13. In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance.
Porpiglia F; Cantiello F; De Luca S; Manfredi M; Veltri A; Russo F; Sottile A; Damiano R
BJU Int; 2016 Oct; 118(4):527-34. PubMed ID: 26350955
[TBL] [Abstract][Full Text] [Related]
14. MRI in active surveillance: a critical review.
Stavrinides V; Giganti F; Emberton M; Moore CM
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):5-15. PubMed ID: 30115960
[TBL] [Abstract][Full Text] [Related]
15. The role of multi-parametric MRI in loco-regional staging of men diagnosed with early prostate cancer.
Appayya MB; Johnston EW; Punwani S
Curr Opin Urol; 2015 Nov; 25(6):510-7. PubMed ID: 26372039
[TBL] [Abstract][Full Text] [Related]
16. MRI and surveillance.
Ouzzane A; Puech P; Villers A
Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia.
Gordon LG; James R; Tuffaha HW; Lowe A; Yaxley J
J Magn Reson Imaging; 2017 May; 45(5):1304-1315. PubMed ID: 27726240
[TBL] [Abstract][Full Text] [Related]
18. Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance.
Mamawala MK; Meyer AR; Landis PK; Macura KJ; Epstein JI; Partin AW; Carter BH; Gorin MA
BJU Int; 2020 Jun; 125(6):861-866. PubMed ID: 32039537
[TBL] [Abstract][Full Text] [Related]
19. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
[TBL] [Abstract][Full Text] [Related]
20. The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer.
Schulman AA; Sze C; Tsivian E; Gupta RT; Moul JW; Polascik TJ
Curr Urol Rep; 2017 Jul; 18(7):52. PubMed ID: 28589398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
